RESULTS
17 matchesAllox raises funds to support allosteric drug discovery platform
Allox (Allostery Exploration Technologies SL) has raised $10.5 million in seed financing, the proceeds from which will be used to scale and expand the company’s platform capabilities and…
FDA clears IND application for Frontier’s FMC-242
Frontier Medicines Corp. announced that the U.S. FDA has cleared its IND application for FMC-242 for the treatment of select advanced solid tumors.
UGX-301 protects the retina through dual complement targeting
Researchers from Suzhou Ugenex Therapeutics Co. Ltd. presented the preclinical characterization of UGX-301, a bicistronic gene therapy designed to simultaneously target the classical and alternative complement activation pathways…
Multitarget anticonvulsant has enhanced brain exposure
Researchers at Tanta University and collaborators described a new series of multifunctional anticonvulsants combining AMPA receptor antagonism, Nav1.2 channel blockade and antioxidant neuroprotective activity.
CDA biodegrader enhances therapeutic efficacy of deoxycytidine analogues
Gemcitabine and cytarabine are deoxycytidine (dC) analogue prodrugs used against solid tumors and blood cancers, but their activity is limited by several resistance mechanisms involving drug uptake, activation…
EU-funded consortium to advance secretome-based therapy for osteoarthritis
The ExocordOA consortium has announced the launch of a 5-year, €13 million (US$17.2 million) project, funded by Horizon Europe, to advance extracellular vesicle-enriched secretome therapies toward clinical use,…
Astellas licenses option for Audax’s lead immuno-oncology candidate
Astellas Pharma Inc. and Audax Biosciences Pty Ltd. have entered into an exclusive option and license agreement for Audax’s lead immuno-oncology candidate, DAX-044, a novel immune-targeted IL-12 antibody-cytokine…
Rumi Therapeutics signs deal with Enthorin for fragile X program
Rumi Therapeutics, part of Rumi Scientific Holdings, has announced an option to license agreement with Enthorin Therapeutics LLC to advance RTX-7340 (ENT-7340), an investigational phosphodiesterase 2 (PDE2) inhibitor,…
ALS Association award supports Acurastem’s UNC13A program
Acurastem Inc. has been granted a 2-year, $1 million Hoffman ALS Clinical Trial Award from the ALS Association to support the company’s UNC13A program and biomarker development for…
Cavity-reduced prefusion RSV F vaccine delivers durable, broad protection
Respiratory syncytial virus (RSV) causes approximately 3.6 million hospitalizations and 100,000 deaths annually among children under 5 years, creating a major need for durable vaccines. The RSV fusion…
Multivalent pDNA vaccine prolongs BCG-mediated control of M. tuberculosis
Mycobacterium tuberculosis remains a leading cause of infectious disease-mediated death, with 10.8 million reported cases of active disease and 1.25 million deaths only in 2023. The Bacillus Calmette-Guerin…
New DAGLA variant tied to neuro-ocular phenotype
The endocannabinoid system is a neuromodulatory network that plays a crucial role in brain development and neuronal signaling. DAGLA is a gene that encodes diacylglycerol lipase α, a…
Medicenna’s MDNA-209 extends survival in GVHD models
Medicenna Therapeutics Corp. has released new preclinical data for MDNA-209, a long-acting IL-2/IL-15 superantagonist that effectively blocks the overactive CD122/CD132 pathway responsible for autoimmune diseases. The results demonstrated…
ADX-038 shows sustained alternative complement inhibition
Researchers from Adarx Pharmaceuticals Inc. presented preclinical and early clinical data on agazisiran (ADX-038), a double-stranded, GalNAc-conjugated siRNA developed to reduce complement factor B (CFB) expression.
MARY-1 improves kidney function in DKD and AKI models
The serotonin 5-HT2B receptor has been implicated in maladaptive responses to renal injury, including inflammatory and fibrotic signaling, making it a potential therapeutic target. Researchers from the University…
Spyre Therapeutics antibodies, alone and in combination, ameliorate IBD phenotype
Spyre Therapeutics Inc. has developed and presented data for a series of antibodies with extended half-life, and their combination, for the treatment of inflammatory bowel disease (IBD). These…
ESMO 2026: Applying AI across tumor types
Tumor-agnostic biology as a field is well-suited to AI in principle. It has simply massive amounts of highly complex data spanning multiple individual fields – a great place…